BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

July 30, 2012 7:00 AM UTC

Almirall S.A. (Madrid:ALM) gained €0.14 to €6.17 last week while Forest Laboratories Inc. (NYSE:FRX) lost $0.86 to $34.04 after the European Commission approved an MAA from Almirall and FDA approved an NDA from Forest for aclidinium bromide as maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).

Almirall plans to launch the product as Bretaris/Eklira Genuair in Europe this year with co-commercialization partner Menarini Group. Forest will market the product in the U.S. as Tudorza Pressair...